DR. DANIEL WEINER has been a director of the Company since May 1, 2017, served as Lead Independent Director of the Board from October 20, 2022, to December 17, 2024, and was appointed as Chairman of the Board on December 17, 2024. Dr. Weiner is also an independent director of Simmunone, Inc. Dr. Weiner graduated from the University of Kentucky with a doctoral degree in Mathematical Statistics, with an emphasis on compartmental modeling. Dr. Weiner has served as an expert consultant to the U.S. Food and Drug Administration ( FDA ) on pharmacokinetic modeling and bioequivalence assessment and is the 2022 American Society for Clinical Pharmacology & Therapeutics ( ASCPT ) recipient of the Sheiner-Beal Award in Pharmacometrics. Dr. Weiner is a Fellow of the American Statistical Association ( ASA ). Dr. Weiner has held senior management positions at companies such as Merrell Dow Pharmaceuticals; Statistical Consultants, Inc. (founder); Syntex Development Research; Certara Inc.; Pharsight Corp.; Quintiles, Inc. (now IQVIA); and IVAX Research, where he had operational responsibilities as well as assisting with M&A activities. Dr. Weiner is an Adjunct Professor with the Division of Pharmacotherapy and Experimental Therapeutics in the School of Pharmacy, University of North Carolina. He is the original designer/author of the WinNonlin family of PK/PD Modeling Software and is the co-author of Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Dr. Weiner previously served as a Board member of DILIsym Services, Inc. ( DILIsym ), which was merged into the Company in September 2021. We believe that Dr. Weiner s extensive industry knowledge, expertise, and experience make him a qualified candidate for the Board.